1. Scrip
  2. >>Business
  3. >>Earnings

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

 
• By Alaric DeArment

CEO Daniel O’Day highlighted Gilead’s large pipeline and relative safety from patent expirations over the next few years in the company’s Q1 earnings call.

• Source: Shutterstock

Gilead Sciences, Inc. is looking to expand its CAR-T cell therapy offerings beyond currently approved CD19-directed products and an investigational anti-BCMA candidate to include off-the-shelf options and CAR-Ts for autoimmune diseases. But despite kicking off the year with a multibillion-dollar liver disease play with the acquisition of CymaBay Therapeutics, Inc., the company does not see further major acquisitions happening anytime soon.

The Foster City, CA-based drug maker announced its first quarter 2024 earnings on 25 April, reporting total revenues of $6.7bn, a 5% increase over the comparable period in 2023, with increased sales for HIV, oncology and liver disease drugs driving that growth

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.